Contact your healthcare provider promptly to report the incident
While research is rapidly evolving, vascular neurologist Pierre Fayad, MD, says drugs like Ozempic and Wegovy, part of a medication class called GLP-1 agonists, are showing a range of promising results beyond diabetes treatment and weight loss
The underlying reason for taking semaglutide is typically weight management, and probiotic strains with published RCT data on weight endpoints (body fat mass, waist circumference, energy intake) engage adjacent biology to the prescription drug
Its authors found that use of semaglutide reduced: deaths from causes related to cardiovascular disease by 17% hospitalizations for heart failure by 76% non-fatal myocardial infarction (heart attack) by 24% the need for coronary revascularization by 24% strokes in people with diabetes by 35% deaths from any cause by 21%
Feel inspired by these Wegovy before-and-after pictures